摘要
目的分析阿比特龙(ABI)、多西他赛(DOC)分别联合泼尼松对转移性去势抵抗性前列腺癌(mCRPC)的近期疗效及对患者疾病相关血清指标的影响。方法选取2022年1月至2023年4月皖南医学院第二附属医院收治的64例mCRPC患者作为研究对象。采用随机数字表法分为试验组和对照组,各32例。试验组接受ABI联合泼尼松治疗,对照组接受DOC联合泼尼松治疗。比较两组治疗后近期疗效,比较两组治疗前后疾病相关血清指标及尿流动力学指标,比较两组治疗期间不良反应发生情况。结果治疗后,试验组近期疾病控制率高于对照组,差异具有统计学意义(P<0.05)。与治疗前比较,治疗后两组前列腺特异性抗原(PSA)、睾酮(T)、细胞角蛋白19片段(CYFRA21-1)、剩余尿量及神经元特异性烯醇化酶(NSE)水平降低,且试验组低于对照组,差异具有统计学意义(P<0.05)。与治疗前比较,治疗后两组最大尿流率均升高,且试验组高于对照组,差异具有统计学意义(P<0.05)。试验组治疗期间不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论ABI联合泼尼松对mCRPC的近期疗效优于DOC联合泼尼松,可更好地调节疾病相关血清指标,改善尿流动力学,安全性更高。
Objective To analyze the short-term efficacy of abiraterone(ABI)and docetaxel(DOC)combined with prednisone in patients with metastatic castration-resistant prostate cancer(mCRPC)and the effects on disease-related serum indexes.Methods A total of 64 mCRPC patients admitted to the Second Affiliated Hospital of Wannan Medical College from January 2022 to April 2023 were selected as the study objects.They were divided into the experimental group and the control group by random number table method,with 32 cases each.The experimental group received ABI combined with prednisone,and the control group received DOC combined with prednisone.The short-term efficacy of the two groups after treatment was compared,the disease-related serum indexes and urodynamics indexes of the two groups before and after treatment were compared,and the occurrence of adverse reactions during treatment was compared between the two groups.Results After treatment,the short-term disease control rate of experimental group was higher than that of control group,and the difference was statistically significant(P<0.05).Compared with before treatment,the levels of prostate-specific antigen(PSA),testosterone(T),cytokeratin 19 fragment(CYFRA21-1),residual urine volume and neurone-specific enolase(NSE)in both groups decreased after treatment,and the experimental group was lower than control group,with statistically significant differences(P<0.05).Compared with before treatment,the maximum urine flow rate of both groups increased after treatment,and the experimental group was higher than control group,with statistically significant difference(P<0.05).The adverse reactions during treatment of experimental group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusions ABI combined with prednisone has better short-term efficacy in mCRPC than DOC combined with prednisone,which could better regulate disease-related serum indexes,improve urodynamics and has better safety.
作者
吴瑛月
刘孟雪
王允武
许锦英
WU Yingyue;LIU Mengxue;WANG Yunwu;XU Jinying(Department of Pharmacy,the Second Affiliated Hospital of Wannan Medical College,Wuhu 241000,Anhui,China;Department of Urology,the Second Affiliated Hospital of Wannan MedicalCollege,Wuhu 241000,Anhui,China)
出处
《中国性科学》
2024年第6期39-42,共4页
Chinese Journal of Human Sexuality
